Press Releases Amarin Corporation plc

Equities

AMRN

US0231112063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.7781 ^USD	-3.37%		+15.62%	-10.56%

Jun. 12	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	MT
Jun. 11	European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amarin Board of Directors Announces CEO Transition	Jun. 04	GL
Amarin Board of Directors Announces CEO Transition	Jun. 04	AQ
AMARIN RECEIVES NATIONAL REIMBURSEMENT FOR VAZKEPA IN GREECE AND ANNOUNCES EXCLUSIVE MARKETING AND COMMERCIALIZATION AGREEMENT WITH VIANEX S.A.	May. 29	AQ
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.	May. 28	GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 06	GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 06	AQ
Amarin: Q1 Earnings Snapshot	May. 01	AQ
Amarin Reports First Quarter 2024 Business Update and Financial Results	May. 01	GL
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event	Apr. 24	GL
Amarin Announces Results of Annual General Meeting of Shareholders	Apr. 22	GL
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024	Apr. 15	GL
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24	Apr. 08	GL
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 08	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	Apr. 03	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	Apr. 03	AQ
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo	Mar. 25	GL
Amarin: Q4 Earnings Snapshot	Feb. 29	AQ
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amarin Corporation plc

Equities

AMRN

US0231112063

Press Releases

Filters